Effect of Zuranolone vs Placebo in MDD

Figure 2. Improvements in Depressive Symptoms (mFAS); (A) Change From Baseline in HDRS-17 Total Score Over Time and (B) Change From Baseline in MADRS Total Score Over Time

A. CFB HDRS-17 Total Score Over Time

B. CFB MADRS Total Score Over Time

*HDRS-17 score was calculated as the sum of the 17 individual item scores. A negative change indicates improvement. Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline HDRS-17, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point–by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity. Shaded area represents the 14-day treatment period.

The MADRS was calculated as the sum of the 10 individual item scores. A negative change indicates improvement. Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline MADRS, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point–by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity. Shaded area represents the 14-day treatment period.

*P < .05 vs placebo. †P < .01 vs placebo.

Abbreviations: CFB = change from baseline, HDRS-17 = 17-item Hamilton Depression Rating Scale total score, LSM = least-squares mean, MADRS = Montgomery-Asberg Depression Rating Scale, mFAS = modified full analysis set, n = number of patients on that day, SOC = standard of care.